As part of its participation in the [removed]Montreal Protocol on Substances that Deplete the Ozone Layer[/removed], the FDA has published its timeline for removing seven metered-dose inhalers (MDI) used to deliver asthma and COPD medications from U.S. shelves.

Specifically, the Tilade Inhaler (nedocromil), Alupent Inhalation Aerosol (metaproterenol), and Azmacort Inhalation Aerosol (triamcinolone), Intal Inhaler (cromolyn) will be unavailable after 2010; the Aerobid Inhaler System (flunisolide) will be sold through mid-2011; and both Combivent Inhalation Aerosol (albuterol and ipratropium in combination), Maxair Autohaler (pirbuterol) will be on shelves through the end of 2013.

The FDA has also published a list of alternatives that do not possess ozone-depleting chlorofluorocarbons (CFCs).